284 6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33–39 7. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP (2001) Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 98(19):10823–10828 8. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W et al (2011) Reprogramming transcription by distinct classes of enhancers functionally deﬁned by eRNA. Nature 474(7351):390–394 9. Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS (2011) High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology 58(5):766–772 10. Linja MJ, Visakorpi T (2004) Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92(4):255–264 11. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102(4):1151–1156 12. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their dis- tinctive transcriptional activities. Prostate [Epub ahead of print] 13. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107(39):16759–16765 14. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6):2305– 2313 15. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4):e19059 16. Balk SP, Knudsen KE (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001 17. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Be- roukhim R et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2):245–256 18. Lonard DM, Lanz RB, O’Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28(5):575–587 19. Agoulnik IU, Weigel NL (2009) Coactivator selective regulation of androgen receptor activity. Steroids 74(8):669–674 20. Agoulnik IU, Vaid A, Bingman WE, 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM et al (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor pro- gression. Cancer Res 65(17):7959–7967 21. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, 3rd, Erdem H, Frolov A, Smith CL et al (2006) Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66(21): 10594–10602 22. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY et al (2005) SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65(17):7976–7983 23. Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee LY, Tsai SY et al (2008) Steroid receptor coactivator-3/AIB1 pro- motes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 68(13):5460–5468 123 World J Urol (2012) 30:279–285 24. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB et al (2007) Inﬂammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256–269 25. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z (2000) Immunohistochemical localization of interleukin-6 and its receptor in benign, prema- lignant and malignant prostate tissue. J Pathol 191(3):239–244 26. Culig Z (2011) Cytokine disbalance in common human cancers. Biochim Biophys Acta 1813(2):308–314 27. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC (2009) Interleukin-6 increases prostate cancer cells resistance to bica- lutamide via TIF2. Mol Cancer Ther 8(3):665–671 28. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K et al (2008) The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen- independent growth. Cancer Res 68(16):6762–6769 29. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q et al (2010) Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 70(8):3309–3319 30. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE (2007) Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 38(11):1611–1620 31. Li Y, Li CX, Ye H, Chen F, Melamed J, Peng Y, Liu J, Wang Z et al (2008) Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med 12(6B):2790–2798 32. Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M et al (2011) Determining prostate cancer-speciﬁc death through quantiﬁcation of stromo- genic carcinoma area in prostatectomy specimens. Am J Pathol 178(1):79–87 33. Song K, Wang H, Krebs TL, Kim SJ, Danielpour D (2008) Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res 68(19):8173–8182 34. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10(3):233–239 35. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, Levink R, Coumans F et al (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69(7):2912–2918 36. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G et al (2011) Activation of NF-{kappa}B by TMPRSS2/ ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71(4):1325–1333 37. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J et al (2010) An integrated network of androgen receptor, poly- comb, and TMPRSS2-ERG gene fusions in prostate cancer pro- gression. Cancer Cell 17(5):443–454 38. van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA (2007) The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer speciﬁc survival: a long-term follow-up study. Prostate 67(13):1432–1438 39. Pontes J Jr, Srougi M, Borra PM, Dall’ Oglio MF, Ribeiro-Filho LA, Leite KR (2010) E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 18(2):179–184